Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan on November 10 and 11, 2025.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving common stock.
• On November 10, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• Concurrently on November 10, 2025, 4,000 shares of common stock were sold at weighted average prices of $448.2675 (3,500 shares) and $449.22 (500 shares).
• On November 11, 2025, Rothblatt exercised another 4,000 stock options at an exercise price of $120.26 per share.
• Also on November 11, 2025, 4,000 shares of common stock were sold at weighted average prices of $450.6427 (1,097 shares), $451.8664 (1,634 shares), and $452.7807 (1,269 shares).
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
• Following these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 166 shares by spouse, 324,518 shares by Trust (6), 258,117 shares by Trust (7), 45,596 shares by Trust (8), and 15,962 shares by Trust (9).
• The reporting person also beneficially owns 106,000 derivative securities (stock options) following the reported transactions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these transactions are part of a pre-arranged 10b5-1 plan, which reduces concerns about opportunistic selling. The significant profit realized by the insider is a positive for the individual but does not directly impact the company's operational outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a systematic approach to managing equity rather than opportunistic selling.
• The exercise price of $120.26 is significantly lower than the sale prices (ranging from $448.00 to $453.25), demonstrating substantial profitability for the insider on these option exercises.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence, although this is mitigated by the 10b5-1 plan.

Future Outlook

The filing indicates the continuation of a pre-arranged 10b5-1 trading plan for the reporting person, which will proceed until the earlier of the exhaustion of a tranche of 294,000 stock options expiring March 15, 2026, or December 31, 2025.

Industry Context

This Form 4 filing is specific to an insider's equity transactions and does not provide broader industry context or trends. It reflects individual wealth management and compensation realization within the pharmaceutical/biotechnology sector.

Stakeholder Impact

• Shareholders may interpret the insider selling, even if pre-planned, as a signal, though the existence of a 10b5-1 plan typically mitigates negative perceptions.
• The transactions represent a realization of value for the CEO's compensation, which is a direct benefit to the executive.

Next Steps

• The 10b5-1 trading plan will continue until the earlier of the exhaustion of 294,000 stock options expiring March 15, 2026, or December 31, 2025.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan. These sales are part of a systematic approach to managing equity and compensation, rather than a reaction to new material information about the company's performance or outlook. While insider selling can sometimes be a bearish signal, the pre-planned nature of these transactions suggests it's not indicative of a change in management's fundamental view of the company's prospects. Therefore, a 'hold' recommendation is appropriate, as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

UTHR, United Therapeutics, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, CEO, Equity Sales